Reimbursement Review Reports

The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

Brand Name Sort descending Generic Name Therapeutic Area Recommendation Type Project Status Date Submission Received Date Recommendation Issued
Tivicay Dolutegravir HIV infection List Complete
Toctino Alitretinoin Eczema List with clinical criteria and/or conditions Complete
Toviaz Fesoterodine fumarate Overactive bladder List in a similar manner Complete
Trajenta Linagliptin Diabetes mellitus, type 2 List with clinical criteria and/or conditions Complete
Tramacet Tramadol hydrochloride /acetaminophen Acute pain Do not list Complete
Translarna ataluren Cancelled
Treanda Bendamustine hydrochloride Chronic Lymphocytic Leukemia (relapsed/refractory) Do not reimburse Complete
Treanda Bendamustine hydrochloride Chronic Lymphocytic Leukemia (first-line) Reimburse with clinical criteria and/or conditions Complete
Treanda Bendamustine hydrochloride Non-Hodgkin Lymphoma and Mantle Cell Lymphoma Reimburse Complete
Treanda (in combination with rituximab) Bendamustine hydrochloride Chronic Lymphocytic Leukemia Withdrawn